[HTML][HTML] FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies
C Antoniotti, MM Germani, D Rossini, S Lonardi… - European Journal of …, 2022 - Elsevier
Background We performed a pooled analysis of TRIBE and TRIBE2 studies to assess the
efficacy and safety of the intensification of upfront chemotherapy backbone–from doublets to …
efficacy and safety of the intensification of upfront chemotherapy backbone–from doublets to …
[HTML][HTML] Total Neoadjuvant Treatment for Locally Advanced Rectal Cancer Patients: Where Do We Stand?
V Daprà, M Airoldi, M Bartolini, R Fazio… - International Journal of …, 2023 - mdpi.com
The therapeutic landscape in locally advanced rectal cancer (LARC) has undergone a
significant paradigm shift in recent years with the rising adoption of total neoadjuvant …
significant paradigm shift in recent years with the rising adoption of total neoadjuvant …
[HTML][HTML] Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced …
G Piringer, J Decker, V Trommet, T Kühr, S Heibl… - Frontiers in …, 2023 - frontiersin.org
Metastatic BRAFV600E mutated colorectal cancer is associated with poor overall survival
and modest effectiveness to standard therapies. Furthermore, survival is influenced by the …
and modest effectiveness to standard therapies. Furthermore, survival is influenced by the …
Clinical research progress on BRAF V600E-mutant advanced colorectal cancer
C Zeng, M Wang, S Xie, N Wang, Z Wang, D Yi… - Journal of Cancer …, 2023 - Springer
Colorectal cancer is one of the malignant tumors that pose a serious threat to human health.
A particularly bad prognosis might be expected for colorectal tumors with the unique …
A particularly bad prognosis might be expected for colorectal tumors with the unique …
[HTML][HTML] The curcumin analogue, MS13 (1, 5-Bis (4-hydroxy-3-methoxyphenyl)-1, 4-pentadiene-3-one), inhibits cell proliferation and induces apoptosis in primary and …
The cytotoxic and apoptotic effects of turmeric (Curcuma longa) on colon cancer have been
well documented but specific structural modifications of curcumin have been shown to …
well documented but specific structural modifications of curcumin have been shown to …
[HTML][HTML] The impact of clinical and translational research on the quality of life during the metastatic colorectal cancer patient journey
M Rodriguez Castells, I Baraibar, J Ros… - Frontiers in …, 2023 - frontiersin.org
The journey of metastatic colorectal cancer patients is complex and challenging, requiring
coordination and collaboration between multiple healthcare providers. Understanding …
coordination and collaboration between multiple healthcare providers. Understanding …
Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer
MG Rodriquenz, D Ciardiello, TP Latiano… - Critical Reviews in …, 2022 - Elsevier
Abstract Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC)
harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better …
harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better …
[HTML][HTML] Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 …
R Moretto, D Rossini, G Zucchelli, S Lonardi… - European Journal of …, 2020 - Elsevier
Background Oligometastatic disease (OMD) identifies tumours with limited metastatic
spread. OMD definition is not univocal and no data from clinical trials are available about the …
spread. OMD definition is not univocal and no data from clinical trials are available about the …
[HTML][HTML] Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled …
E Assenat, C de La Fouchardière, F Portales, M Ychou… - ESMO open, 2021 - Elsevier
Background Nab-paclitaxel/gemcitabine (AG) and FOLFIRINOX (FFX) are promising drugs
in metastatic pancreatic cancer (MPC). This study evaluated a new first-line sequential …
in metastatic pancreatic cancer (MPC). This study evaluated a new first-line sequential …
[HTML][HTML] A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies …
E Wensink, M Bond, E Kucukkose, A May, G Vink… - Cancer Treatment …, 2021 - Elsevier
In 5% of metastatic colorectal cancer (mCRC) patients, tumours display a deficient mismatch
repair (dMMR) system. Immunotherapy is beneficial in dMMR mCRC patients and has …
repair (dMMR) system. Immunotherapy is beneficial in dMMR mCRC patients and has …